Anacetrapib News and Research

RSS
Update on Merck's development programs for vorapaxar, ER niacin/laropirprant and anacetrapib

Update on Merck's development programs for vorapaxar, ER niacin/laropirprant and anacetrapib

Evacetrapib drug may increase HDL-C and decrease LDL-C levels

Evacetrapib drug may increase HDL-C and decrease LDL-C levels

The Polyclinic participates in major international HDL clinical research study

The Polyclinic participates in major international HDL clinical research study

Merck reports GAAP net income of $861 million for 2010

Merck reports GAAP net income of $861 million for 2010

Researchers report results from Phase III DEFINE study for coronary heart disease

Researchers report results from Phase III DEFINE study for coronary heart disease

Merck reports $342 million net income for 2010 third quarter

Merck reports $342 million net income for 2010 third quarter

HDL cholesterol can transform from good to bad actor in heart-disease process

HDL cholesterol can transform from good to bad actor in heart-disease process

Merck hosts R&D and Business Briefing

Merck hosts R&D and Business Briefing

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions

Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions

Determining success or failure in cholesterol-controlling drugs

Determining success or failure in cholesterol-controlling drugs

Issues on cholesterol: diet, statins and genetics

Issues on cholesterol: diet, statins and genetics